Jean-paul P. Guastalla

28 Rue Laennec
Lyon, 69373, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS.

Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: July 13, 2022

Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trial.

Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trial.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: September 07, 2017

Motivations of patients seeking supportive care for cancer from physicians prescribing homeopathic or conventional medicines: results of an observational cross-sectional study.

Motivations of patients seeking supportive care for cancer from physicians prescribing homeopathic or conventional medicines: results of an observational cross-sectional study.

Journal: Homeopathy : the journal of the Faculty of Homeopathy

Published: August 31, 2016

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

Journal: Breast (Edinburgh, Scotland)

Published: May 23, 2014

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

Journal: The Lancet. Oncology

Published: December 19, 2012

Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.

Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.

Journal: BMC cancer

Published: May 11, 2012

Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization.

Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization.

Journal: Bulletin du cancer

Published: March 30, 2012

Cervix cancer and corpus cancer of the uterus

Cervix cancer and corpus cancer of the uterus

Journal: La Revue du praticien

Published: February 01, 2012

Thrombosis and breast cancer: incidence, risk factors, physiopathology and treatment

Thrombosis and breast cancer: incidence, risk factors, physiopathology and treatment

Journal: Bulletin du cancer

Published: January 31, 2012

Adjuvant treatments in breast cancer: interest of completion of axillary dissection in case of micrometastases or isolated tumor cells in sentinel lymph node

Adjuvant treatments in breast cancer: interest of completion of axillary dissection in case of micrometastases or isolated tumor cells in sentinel lymph node

Journal: Bulletin du cancer

Published: January 24, 2012

First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.

First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.

Journal: Bulletin du cancer

Published: January 20, 2012

Antihormonal therapy in breast cancer and mTOR inhibitors

Antihormonal therapy in breast cancer and mTOR inhibitors

Journal: Bulletin du cancer

Published: December 03, 2011

Showing 1-12 of 15

Last Updated: 09/26/2026